Ardena, a Belgium-based CDMO, will nearly triple the length of its Swedish plant as part of a €35 million investment in its European operations. The company supports the manufacture of medicinal ingredients in Södertälje to build its capacity and includes a new production line and a larger HPLC preparative system, as well as a new freeze-drying unit and other large-scale synthesis equipment.
The facility will grow from its current construction of 1500 m2 to a total area of more than 4000 m2 for laboratories and offices until the end of 2023.
“By the end of 2023, Ardena will have increased GMP production capacity from our pharmaceutical substance services, adding autonomous purification and freeze-drying capabilities,” said Harry Christiaens, Chief Executive Officer. “This investment is in line with the expected expansion and will allow us to continue to meet the long-term visitor collaboration demands as well as Ardena’s expertise in drug substances. “
Scheduled to be installed and qualified in the fourth quarter of 2022, the increased capacity will enable 4 times the production speed of existing preparative HPLC, he adds. A new tangential filtration/ultrafiltration (TFF/UF) will supply purification and concentration of PLCs and chemical compounds employing a continuous procedure design.
Freeze-drying of up to 55 liters for greater concentration and isolation of natural fabrics will be operational in 2023. Synthetic devices ranging from 50 liters to 2300 liters will also be upgraded with more reactors.
“TFF allows us to insulate natural fabrics very quickly,” says Christiaens. “This new equipment, combined with our existing configuration, results in a flexible and flexible production unit. We are confident that our continued investment in these technologies will gain massive advantages for our customers. “